Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative efficacy of common thrombolytics in acute ischaemic stroke: a network meta-analysis.

Singapore medical journal·2026

Same author

Knowledge landscape and hotspots of scientific publications on myocarditis: a bibliometric analysis from 2000 to 2024.

Singapore medical journal·2026

Same author

Evaluating the impact of frailty in older adults on functional outcomes post-mechanical thrombectomy: a multicentre study incorporating traditional and machine learning methods.

Journal of thrombosis and thrombolysis·2026

Same author

Refining evidence-based care for diverse bicuspid aortic valve phenotypes: addressing one piece of a larger puzzle.

Heart (British Cardiac Society)·2026

Same author

Phenogroup-based stratification of cardiovascular risk in obstructive sleep apnea.

American journal of preventive cardiology·2026

Same author

Real-world assessment of low-density lipoprotein cholesterol goal, disease burden and financial burden among patients with atherosclerotic cardiovascular disease in Singapore-A single-centre retrospective cohort study.

Frontiers in cardiovascular medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 5, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Interactions between antidiabetes medications and heart-brain axis.

Leong Tung Ong¹, Ching-Hui Sia

¹Department of Cardiology, National University Heart Centre, Singapore.

Current Opinion in Endocrinology, Diabetes, and Obesity

|December 6, 2024

Summary

Antidiabetic drugs show promise for improving heart and brain health in diabetes patients. Further research is needed to confirm these benefits for the heart-brain axis.

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Experiment Videos

Last Updated: Jun 5, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Area of Science:

Cardiovascular Medicine
Neuroscience
Endocrinology

Background:

The heart-brain axis (HBA) describes physiological interactions between cardiovascular and nervous systems.
Diabetes mellitus increases risk for cardiovascular and neurological diseases.
Antidiabetic drugs may influence HBA function, impacting cognitive and cardiac health.

Purpose of the Study:

To review the impact of antidiabetic drugs on the heart-brain axis in patients with diabetes.
To explore how these medications affect cardiovascular and cognitive outcomes.

Main Methods:

Literature review of studies on antidiabetic drugs and their effects on the HBA.
Analysis of mechanisms by which different drug classes influence cardiovascular and neurological health.

Main Results:

Metformin enhances cardiovascular and cognitive function via AMPK activation.
SGLT2 inhibitors reduce inflammation and oxidative stress, benefiting heart failure and neurodegenerative pathology.
DPP-4 inhibitors offer neuroprotection but may increase heart failure risk.
GLP-1 receptor agonists provide neuroprotection but may increase sympathetic activity.

Conclusions:

Antidiabetic medications possess potential to improve cardiovascular and cognitive health.
Further clinical studies are necessary to validate these observed effects on the HBA.